Abstract:Objective: In our previous studies show that bortezomib can enhance the sensitivity of multiple myeloma (MM) cells to the cytotoxity of γδT, nature killer (NK) cells and cytokine-induced killer (CIK) cells, and there is synergistic effect among these three types of cells as well. Therefore, the efficacy and safety of combination of adoptive cellular immunotherapy (ACI) with NK, γδT and CIK cells and bortezomib-based chemotherapy was investigated in this study. Method: 27 patients were recruited in this study with newly-diagnosed MM and received Bortezomib-based therapy during September 2008 and September 2013 in the First Hospital of Jilin University. The patients were divided into study group (ACI plus bortezomib-based therapy) and control group (bortezomib-based therapy alone). There are 14 patients in study group with median age of 60.5 (54-73) years old, while 13 patients in control group with median age of 56 (41-80) years old. In the study group, autologous peripheral blood mononuclear cells (PBMCs) were collected from the peripheral blood by apheresis at the first day, and were induced into NK, γδT and CIK cells, then the expanded immunocytes were infused back to the patients after 14 days culture ex vivo. The number of cells for each transfusion ranged from 1.2×10 9 - 2.0×10 9 cells. Progression-free survival (PFS) and adverse effects were investigated. One course of ACI would be done within 3 weeks and contain six times of infusion in total. This study was approved by the Ethical Committee of the First Hospital of Jilin University. Written informed consent was obtained from all patients before their enrollment into the study. Result: In this study, the percentage of CIK (CD56+CD3+), NK (CD56+CD3-) and γδT (Vγ9+) before and after induction were 4.39% (1.5%-8%) vs 46.32% (27%-50%), 10.35% (5.1%-12.6%) vs 95.28% (70.1%-99.6%), 4.72% (2.61%-11.2%) vs 90.64% (60.5%-97.9%), respectively. The median follow-up time was 18 months. The characteristics including age, gender, stage, chemotherapy regimen etc. had no significant difference between the two groups. The median PFS in study group was 24.5m (12-48), and the median PFS was 12m (5-32) in control group (P=0.018). For subgroup analysis, the median PFS in the study group receiving >3 courses and ≦3 courses group were 36m (24-48) and 20m (12-36), respectively (P=0.141). Among the patients receiving ACI, one patient felt mild fatigue after infusion. One patient had transient fever after one infusion (38 °C) and recovered 1 h later. No other significant side effects were observed. Conclusion: Combination of NK, γδT and CIK cells based ACI and bortezomib-based chemotherapy is well tolerated and shows a great potential to improve the PFS of the patients with MM. This study provided a novel strategy for the treatment of MM, and it is worthwhile to study this combination strategy in multi-center randomized clinical trials. Disclosures No relevant conflicts of interest to declare.

Bortezomib increases the sensitivity of multiple myeloma cells to the cytotoxicity of gamma-delta T cells

Low-dose Bortezomib Increases the Expression of NKG2D and DNAM-1 Ligands and Enhances Induced NK and Γδ T Cell-Mediated Lysis in Multiple Myeloma

Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma

Curcumin Enhances Bortezomib Treatment of Myeloma by Inhibiting Heat Shock Protein 90 Expression

Blockade of HSP70 by VER-155008 Synergistically Enhances Bortezomib-Induced Cytotoxicity in Multiple Myeloma

Synergism of Gambogenic Acid with Bortezomib Induce Apoptosis of Multiple Myeloma.

Gambogenic Acid Synergistically Potentiates Bortezomib-Induced Apoptosis in Multiple Myeloma

Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy

Bortezomib Down-Regulates The Cell-Surface Expression Of Hla Class I And Enhances Natural Killer Cell-Mediated Lysis Of Myeloma

Effects of Bortezomib on Treg Cells in Multiple Myeloma and Its Relationship with Tumor Burden and Chemoresponse

BRD4 Inhibitor Nitroxoline Enhances the Sensitivity of Multiple Myeloma Cells to Bortezomib in Vitro and in Vivo by Promoting Mitochondrial Pathway-Mediated Cell Apoptosis.

Bortezomib Enhanced the Efficacy of CAR-T Therapy Through Up-regulating BCMA Expression in Myeloma Cells

Anti-β2 Microglobulin Monoclonal Antibodies Overcome Bortezomib-Induced Drug Resistance in Multiple Myeloma by Inhibition of Autophagy

Gambogenic Acid Enhances Chemosensitivity of Multiple Myeloma to Bortezomib Through P53/ros/p38 MAPK Apoptotic Pathway

Plasma Enhance Drug Sensitivity to Bortezomib by Inhibition of Cyp1a1 in Myeloma Cells

[Efficacy of Bortezomib Combined Dexamethasone in 24 Patients with Multiple Myeloma].

Bortezomib increases cytotoxic sensitivity of drug-resistant K562 /ADM cells to NK cells and its mechanisms

Effect of bortizomib in combination with modified VAD chemotherapy on multiple myelo-ma

Bortezomib and Il-12 Produce Synergetic Anti-Multiple Myeloma Effects with Reduced Toxicity to Natural Killer Cells

Effects of triptolide on bortezomib-induced apoptosis in multiple myeloma cells]

Combination of Adoptive Cellular Immunotherapy and Bortezomib-Based Regimens Increase the Progression Free Survival of the Patients with Multiple Myeloma